Finally, to support our results with preliminary clinical evidence, we analyzed publicly available datasets using platforms such as TNMplot and UALCAN to investigate whether FLT4 (VEGFR3/CD310) expression could serve as a robust biomarker for stratifying colorectal carcinoma patients suitable for treatment with fruquintinib. Here, FLT4 is linked to colorectal carcinoma.